• Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. Results were presented for the first time in a late-breaking session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients.

    [adsense:336x280:8701650588]

  • Opening for Associate Analyst in Novartis
    2 March 2015
    Opening for Associate Analyst in Novartis

    Novartis (NYSE: NVS) is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
    Headquartered in Basel, Switzerland, Novartis employs nearly 115 000 people in over 140 countries worldwide to help save lives and improve the quality of life. The Group is present in India through Novartis India Limited, listed on the Mumbai Stock Exchange and its wholly owned subsidiaries Novartis Healthcare Private Limited, Sandoz Private Limited and Chiron Behring Vaccines Private Limited.

    Post: Associate Analyst

  • Opening to work as Analytical Scientist I in Novartis | M.Sc. or M.Pharm
    17 February 2015
    Opening to work as Analytical Scientist I in Novartis | M.Sc. or M.Pharm

    Novartis (NYSE: NVS) is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
    Headquartered in Basel, Switzerland, Novartis employs nearly 115 000 people in over 140 countries worldwide to help save lives and improve the quality of life. The Group is present in India through Novartis India Limited, listed on the Mumbai Stock Exchange and its wholly owned subsidiaries Novartis Healthcare Private Limited, Sandoz Private Limited and Chiron Behring Vaccines Private Limited.

    Post: Analytical Scientist I

  • Career opportunity for Senior Clinical Safety Scientist in Novartis
    13 February 2015
    Career opportunity for Senior Clinical Safety Scientist in Novartis

    A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

    Post: Senior Clinical Safety Scientist

  • Opportunity for Senior Analyst-Analytics in Novartis
    10 February 2015
    Opportunity for Senior Analyst-Analytics in Novartis

    Novartis (NYSE: NVS) is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
    Headquartered in Basel, Switzerland, Novartis employs nearly 115 000 people in over 140 countries worldwide to help save lives and improve the quality of life. The Group is present in India through Novartis India Limited, listed on the Mumbai Stock Exchange and its wholly owned subsidiaries Novartis Healthcare Private Limited, Sandoz Private Limited and Chiron Behring Vaccines Private Limited.

    Post: Senior Analyst-Analytics

  • Opportunity for Senior Clinical Manager in Novartis
    9 February 2015
    Opportunity for Senior Clinical Manager in Novartis

    Novartis (NYSE: NVS) is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
    Headquartered in Basel, Switzerland, Novartis employs nearly 115 000 people in over 140 countries worldwide to help save lives and improve the quality of life. The Group is present in India through Novartis India Limited, listed on the Mumbai Stock Exchange and its wholly owned subsidiaries Novartis Healthcare Private Limited, Sandoz Private Limited and Chiron Behring Vaccines Private Limited.

    Post: Senior Clinical Manager

  • Career as Clinical Coding Specialist in Novartis
    1 February 2015
    Career as Clinical Coding Specialist in Novartis

    A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

    Post: Clinical Coding Specialist

  • Work as PVE/ Senior PVE in Novartis
    1 February 2015
    Work as PVE/ Senior PVE in Novartis

    A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

    Post: PVE/Sr.PVE

  • Work as Clinical Data Manager in Novartis
    18 January 2015
    Work as Clinical Data Manager in Novartis

    A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

    Post: Clinical Data Manager

  • Opening for Senior Analyst BA in Novartis
    15 January 2015
    Opening for Senior Analyst BA in Novartis

    A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

    Post: Senior Analyst BA

Subscribe to Novartis